Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study

Secukinumab, a fully human monoclonal antibody neutralizing interleukin‐17A, has been shown to have significant efficacy in the treatment of moderate to severe psoriasis. Long‐term (3‐year) efficacy and safety of secukinumab in Japanese patients with moderate to severe psoriasis were evaluated in an...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Dermatol
Asıl Yazarlar: Okubo, Yukari, Ohtsuki, Mamitaro, Morita, Akimichi, Yamaguchi, Masako, Shima, Tomohiro, Tani, Yumiko, Nakagawa, Hidemi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590222/
https://ncbi.nlm.nih.gov/pubmed/30672623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.14761
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller